A Nation-wide Multicenter Clinical Epidemiologic Study of Chinese Females With Advanced Breast
1 other identifier
observational
4,200
1 country
19
Brief Summary
To study the epidemiological trends and characteristics for advanced breast cancer patients, to analyze these trends and report the results
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Apr 2016
19 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2016
CompletedFirst Submitted
Initial submission to the registry
November 29, 2016
CompletedFirst Posted
Study publicly available on registry
February 9, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2017
CompletedFebruary 9, 2017
February 1, 2017
1 year
November 29, 2016
February 7, 2017
Conditions
Outcome Measures
Primary Outcomes (1)
Survival status at 3 years
percentage of patients still alive at 3 years
3 years
Secondary Outcomes (2)
PFS
3 years
Survival status at 5 years
3 years
Interventions
standard therapy for advanced/metastatic breast cancer
Eligibility Criteria
A total of 21 hospitals were selected in this study. The investigators recruited 4200 advanced BC cases, who were first diagnosed with advanced BC from January 1st, 2012 to December 31st, 2014 from these hospitals.
You may qualify if:
- diagnosed as advanced breast cancer during Jan1st,2012-Dec31st,2014
- complete with surgical pathology data, auxiliary treatment, there is a clear recurrence, transfer time, place, transfer of recurrence after treatment, and curative effect evaluation details.In any age, ethnic group cases.
You may not qualify if:
- no available medical record
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (19)
The 307th Hospital of Military Medical Sciences
Beijing, China
Sichuan Cancer Hospital and Institute
Chengdu, China
The First Affliated Hospital of Chongqing Medical University
Chongqing, China
FuZhou General Hospital of National Miltary Command
Fuzhou, China
Sun Yat-Sen University Cancer Center
Guangzhou, China
Harbin Medical University Cancer Hospital
Harbin, China
Henan Cancer Hospital
Henan, China
Hunan Cancer Hospital
Hunan, China
Jiangsu Provinces hospital
Jiangsu, China
Tumor Hospital of Yunnan Province
Kunming, China
Liaoning Cancer Hospital, Zhejiang Cancer Hospital
Liaoning, China
General Hospital of NingXia Medical University
Ningxia, China
Fudan University Shanghai Cancer Center
Shanghai, China
The First Hospital of China Medical University
Shenyang, China
Tianjin Medical University Cancer Institute & Hospital
Tianjin, China
Wuhan Union Hospital
Wuhan, China
The First Hospital of Xi'an Jiaotong University
Xi'an, China
Xinjiang Medical University Cancer Hospital
Xinjiang, China
FuJian Provincial Cancer Hospital
Zhengzhou, China
Related Publications (4)
Han YQ, Yi ZB, Yu P, Wang WN, Ouyang QC, Yan M, Wang XJ, Hu XC, Jiang ZF, Huang T, Tong ZS, Wang SS, Yin YM, Li H, Yang RX, Yang HW, Teng YE, Sun T, Cai L, Li HY, Ouyang XN, He JJ, Liu XL, Yang SE, Qiao YL, Fan JH, Wang JY, Xu BH. Comparisons of Treatment for HER2-Positive Breast Cancer between Chinese and International Practice: A Nationwide Multicenter Epidemiological Study from China. J Oncol. 2021 Sep 15;2021:6621722. doi: 10.1155/2021/6621722. eCollection 2021.
PMID: 34567118DERIVEDGuo F, Yi Z, Wang W, Han Y, Yu P, Zhang S, Ouyang Q, Yan M, Wang X, Hu X, Jiang Z, Huang T, Tong Z, Wang S, Yin Y, Li H, Yang R, Yang H, Teng Y, Sun T, Cai L, Li H, Chen X, He J, Liu X, Yang S, Fan J, Qiao Y, Wang J, Xu B. Profile, treatment patterns, and influencing factors of anthracycline use in breast cancer patients in China: A nation-wide multicenter study. Cancer Med. 2021 Oct;10(19):6744-6761. doi: 10.1002/cam4.4215. Epub 2021 Sep 2.
PMID: 34472719DERIVEDWu Y, Han Y, Yu P, Ouyang Q, Yan M, Wang X, Hu X, Jiang Z, Huang T, Tong Z, Wang S, Yin Y, Li H, Yang R, Yang H, Teng Y, Sun T, Cai L, Li H, Chen X, He J, Liu X, Yang S, Qiao Y, Fan J, Wang J, Xu B. Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: A Nation-Wide Multicenter Epidemiological Study in China. Front Oncol. 2021 Feb 11;10:599604. doi: 10.3389/fonc.2020.599604. eCollection 2020.
PMID: 33643905DERIVEDYi ZB, Yu P, Zhang S, Wang WN, Han YQ, Ouyang QC, Yan M, Wang XJ, Hu XC, Jiang ZF, Huang T, Tong ZS, Wang SS, Yin YM, Li H, Yang RX, Yang HW, Teng YE, Sun T, Cai L, Li HY, Chen X, He JJ, Liu XL, Yang SE, Wang JY, Fan JH, Qiao YL, Xu BH. Profile and outcome of receptor conversion in breast cancer metastases: a nation-wide multicenter epidemiological study. Int J Cancer. 2021 Feb 1;148(3):692-701. doi: 10.1002/ijc.33227. Epub 2020 Aug 19.
PMID: 32700765DERIVED
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Binghe Xu
Chinese Academy of Medical Sciences
- PRINCIPAL INVESTIGATOR
Youlin Qiao
Chinese Academy of Medical Sciences
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
November 29, 2016
First Posted
February 9, 2017
Study Start
April 1, 2016
Primary Completion
April 1, 2017
Study Completion
December 1, 2017
Last Updated
February 9, 2017
Record last verified: 2017-02
Data Sharing
- IPD Sharing
- Will not share